Icon

REVLIMID (nda021880)- (2.5MG,5MG,10MG,15MG,20MG,25MG)

LENALIDOMIDE BRISTOL MYERS SQUIBB
2.5MG,5MG,10MG,15MG,20MG,25MG
Yes No
2028-Mar-08 2010-Dec-27
2013-Jun-29 None
None No
REVLIMID is a thalidomide analogue indicated for the treatment of adult patients with:  Multiple myeloma (MM), in combination with dexamethasone.  MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT).  Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities.  Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.  Previously treated follicular lymphoma (FL), in combination with a rituximab product.  Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product.
13 1 11
Total Other Developers 13
Drugs with Suitability No
2.5MG ** ** - - -
5MG ** ** - - -
10MG ** ** - - -
15MG ** ** - - -
20MG ** ** - - -
25MG ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 9
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ** ****** ****** **** ******** ********* *** *** *********** ****** ** *** & ***, ******* **** ****, ********* *******, ********-************* ******, *******-*********** ********, *********, ********* ******, ***** (***) ***
****** ** ****** **.*****'* ************ ******* *********** ** ** ** & ** ** **, ***** - ***, ****, *******,, *************, ****** ******* *** ***, ***** (***) ***
****** ***** ****** ***** ************ ******* *********** **** **. *-*/*&* *******, (******* ******** ****) ******, ******* ***** *.*. **. **, ***-******, ****-*********, *********, ******* ******, ***** (***) ***
****** ****** ****** ***. *********** *** ******* *****, *******, ******* *** ***, ****** (***) ***
****** *** ***** *** ************** ********** ******* *********** ****** **. ****, *****, ***** ********* ** ***** *** ***** ****** *** ***** *** *** ******, ***** (***) ***
****** ***** ****** ***** ****** ************ ******* *********** ****-*, **. **. ***, *** & ***, ******* *******, ********* ******, *******-**********, ********* ******, ***** (***) ***
****** ***** ******* *********** *********** *** ****** *** ******, ********, ******** *** ***, ****** (***) ***
****** ***** ***** ******* *** *********** ***, ***, ***, *****, ** *****, ********** **** ***********-****** **** ****, *********, ********* ******, ***** (***) ***
****** ****** **** *** * ****** **** ******* *********** **** *, **. **.: ***, ***, *** & ***, ***** *********** ***, ********* *******, ************, ********* ******, ***** (***) ***
****** ***** **** ***** ****** ******* *********** ****** ********, ******, **********, ********* *** ***, ***** (***) ***
****** ***** ***** ** *** ***** ************** **., ***. ****** ***** *********** **. ** ********* *** **., ******* *******, ****** ****,****** ******, - *****, ****** (***) ***
****** ***** ***** ******* *** *********** **********, *** ****** ****, *********, ********* ******, ***** (***) ***
****** ***** ******* *********** *********** *** ****** *** ******, ********, ******** *** ***, ****** (***) ***
****** ***** ***** ******* *** *********** ***, ***, ***, *****, ** *****, ********** **** ***********-****** **** ****, *********, ********* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.